Observational studyAdvances in therapy2026
Uncontrolled Status, Disease Burden, and Associated Risk Factors Among Patients with Asthma Receiving Medium-to-High Dose ICS or ICS/LABA: A Retrospective Analysis.
Observational study in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is limited information on the uncontrolled status and burden of asthma among patients using inhaled corticosteroids (ICS) combined or not with long-acting β2-agonists (LABA) in China. This study aims to characterize the disease burden among these patients and identify risk factors for unfavorable outcomes.
methodsThis retrospective observational study utilized data from a regional Electronic Medical Record (EMR) database in China. Patients (≥ 12 years) with asthma having at least two prescriptions for medium-to-high dose ICS or ICS/LABA within any 6 months were identified from the Shanghai Medical Database between 2016 and 2020. Data on characteristics and treatment patterns 1-year pre-index (baseline) and disease burden 1-year post-index (follow-up) were obtained from the database. Uncontrolled asthma was defined based on exacerbations and specific treatment. A multivariate logistic regression model was used to identify risk factors associated with the follow-up adverse outcomes.
resultsA total of 35,900 patients with asthma receiving medium-to-high dose ICS or ICS/LABA were included. Of these, 10,842 (30.2%) were uncontrolled at baseline, exhibiting higher proportions of follow-up uncontrolled asthma (32.3% vs. 10.7%), corticosteroids use (16.8% vs. 3.9%), emergency room (ER) visits and hospitalizations due to exacerbations (22.3% vs. 5.2%), and total medical costs (9303.9 CNY vs. 8621.4 CNY) compared to patients who were controlled, all with p < 0.001. Type 2 (T2) biomarkers detection rates were less than 10% during follow-up. Uncontrolled asthma, older age, T2-related comorbidities, use of ≥ 2 controllers, a short-acting β2-agonist (SABA), and corticosteroids at baseline were significantly related to follow-up adverse outcomes.
conclusionA significant proportion of patients with asthma using medium-to-high dose ICS or ICS/LABA in China remain uncontrolled, resulting in greater disease and economic burden. Insufficient assessment of T2 inflammation and suboptimal treatment patterns represent the challenges in asthma management in China, potentially resulting in long-term adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.